{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=112",
    "query": {
      "intervention": "serum sample",
      "page": 112
    },
    "page_size": 10
  },
  "pagination": {
    "page": 112,
    "page_size": 10,
    "total_count": 8384,
    "total_pages": 839,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=113&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=111&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T12:31:38.165Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Positive Gastric Cancer",
        "Colorectal Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "EGFR Positive Solid Tumor",
        "Advanced Solid Tumors",
        "HER2-positive Breast Cancer",
        "Hepatocellular Carcinoma",
        "Non Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Pancreatic Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "FATE-NK100",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2018-01-18",
      "completion_date": "2020-12-15",
      "has_results": false,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03319459"
    },
    {
      "nct_id": "NCT01526057",
      "title": "A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "PF-05280586",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MabThera",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituxan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2012-03-20",
      "completion_date": "2014-05-07",
      "has_results": true,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01526057"
    },
    {
      "nct_id": "NCT01185301",
      "title": "Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "adalimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 395,
      "start_date": "2010-10",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2013-11-15",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 30,
      "location_summary": "Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hemet",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01185301"
    },
    {
      "nct_id": "NCT01939730",
      "title": "Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "1999-08",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01939730"
    },
    {
      "nct_id": "NCT00492167",
      "title": "Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "beta-glucan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "monoclonal antibody 3F8",
          "type": "BIOLOGICAL"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "0 Years to 120 Years"
      },
      "enrollment_count": 45,
      "start_date": "2005-09-09",
      "completion_date": "2022-03-04",
      "has_results": false,
      "last_update_posted_date": "2022-03-07",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492167"
    },
    {
      "nct_id": "NCT00837330",
      "title": "Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "ranibizumab 0.5 or 0.3 mg/0.05 cc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Retina Center, Georgia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2006-05",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00837330"
    },
    {
      "nct_id": "NCT02149264",
      "title": "A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Male Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Testosterone gel (FE 999303)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 160,
      "start_date": "2014-07",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 22,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Newport Beach, California + 19 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02149264"
    },
    {
      "nct_id": "NCT00955630",
      "title": "Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ocular Histoplasmosis Syndrome"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Associates of Kentucky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-08-10",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955630"
    },
    {
      "nct_id": "NCT00276965",
      "title": "Bipolar II Depression: Lithium, SSRI, or the Combination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Sertraline",
          "type": "DRUG"
        },
        {
          "name": "Lithium carbonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 139,
      "start_date": "2006-09",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-05-10",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Palo Alto, California • Mason, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00276965"
    },
    {
      "nct_id": "NCT00826267",
      "title": "6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "lapatinib",
          "type": "DRUG"
        },
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2009-01",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2013-12-31",
      "last_synced_at": "2026-11-11T12:31:38.165Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00826267"
    }
  ]
}